BioticsAI, the winner of TechCrunch Disrupt Battlefield 2023, has recently obtained FDA clearance for its AI software designed to identify fetal abnormalities in ultrasound images. The product, developed by CEO Robhy Bustami, leverages computer vision AI to enhance the quality assessment of fetal ultrasounds, anatomical completeness, automated reporting, and integration into clinical workflows.
Bustami, with a background in obstetrics, aims to address the concerning prenatal outcomes in the U.S., particularly among Black women, who experience a disproportionately high rate of maternal deaths. Recognizing the importance of prenatal ultrasounds, BioticsAI’s technology aims to mitigate misdiagnoses often stemming from low-quality ultrasound images.
Training their AI models on a diverse dataset of hundreds of thousands of ultrasounds, the BioticsAI team faced the challenge of ensuring the technology’s real-world reliability, especially within demographics at the highest risk of adverse outcomes.
This achievement signifies a crucial advancement in AI-powered healthcare solutions and underscores the potential to revolutionize prenatal care by enhancing diagnostic accuracy and maternal health outcomes.
Source: TechCrunch